Pharmaceuticals
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., March 9, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring translational r...
2022-03-09 21:00
2305
Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
SUZHOU, China and ROCKVILLE, Md., March 8, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the results from six preclinical studies of t...
2022-03-09 07:47
4132
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
SEATTLE, Wash. and SUZHOU, China, March 8, 2022 /PRNewswire/ -- ProfoundBio announced that preclinical data from its pipeline of novel, proprietary antibody-drug conjugates (ADCs) and technology will be presented at the American Association for Cancer Research (AACR) Annual Meeting being held Apr...
2022-03-09 06:58
5186
Akeso Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadonilimab in Combination with Docetaxel to Treat NSCLC
HONG KONG, March 7, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the development of innovative antibody drugs, today announced that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the IND...
2022-03-08 11:49
2386
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients
SUZHOU, China, March 6, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its...
2022-03-07 08:18
4113
Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
* Phase 2 study of PVX108 to commence in United States and Australia * Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins University School of Medicine, joins Scientific Advisory Board MELBOURNE, Australia, March 4, 2022 /PRNewswire/ -- Aravax, a clinical stage biotechnology compa...
2022-03-04 21:00
3702
111, Inc. Reaches Strategic Partnership on Direct Supply with Beilin Pharmaceutical to Blaze New Trails in Digital Development of Chinese Patent Medicine
SHANGHAI, March 4, 2022 /PRNewswire/ -- On February 23, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, signed a strategic cooperation agreement on direct supply with Xi'an Beilin Pharmaceutical Co., Ltd. ("Beilin Pharmaceutical")...
2022-03-04 17:24
2665
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a trad...
2022-03-04 09:30
3044
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has gr...
2022-03-03 21:00
2357
Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc.
2022-03-02 20:00
2160
REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER
* Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial * H002 Has Potential To Overcome Resistance Driven By Various EGFR C797S-Containing Mutations in Non-Small Cell Lung Cancer SHANGHAI, March 2, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech com...
2022-03-02 17:27
1648
InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China
BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start ph...
2022-03-02 10:37
2865
ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China
SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing onMarch 1, 2022 and initiate...
2022-03-02 09:07
1775
Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US
SUZHOU, China, March 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("...
2022-03-01 20:30
2576
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial
SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort ...
2022-02-25 22:04
3778
Daewoong Pharmaceutical Announces Successful Phase 3 Topline Results for New Antidiabetic Drug's Triple Combination Therapy
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the topline results of the phase 3 clinical trial for a triple combination therapy of Enavogliflozin, a new antidiabetic drug with the mechanism of SGLT-2 inhibitor, with Metformin and Gemigliptin. Enav...
2022-02-25 22:00
3974
HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets
CHENGDU, China, Feb. 24, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed a three-year drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation ("MTPC"), a Japanese pharma...
2022-02-25 10:00
2207
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer
HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK) announced that the phase III clinical registration study of Trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) has met its primary endpoint. The drug co-developed in Chi...
2022-02-24 13:34
2378
Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China
BEIJING, SHANGHAI and BOSTON, Feb. 23, 2022 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combinationtherapy with Cetuximab at Peking University Cancer Hospital recently. JAB-21822 in combination with ce...
2022-02-24 10:32
2308
Foresee Pharmaceuticals and TRPharm Announce License and Co-Development Agreement
TAIPEI, Feb. 23, 2022 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), aTaiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and ...
2022-02-23 23:00
3014
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 295 media titles]
2026-08-13 23:42Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 294 media titles]
2026-08-10 19:12
Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
16833
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
16606